| --- | --- | --- | --- | |-------------------------|-------|-------|---------------------------------------| | | | | | | | | | | | | | | | | NASDAQ: THTX TSX: TH | | | CORPORATE PRESENTATION April 16, 2021 | Forward-Looking Information | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | The following presentation contains statements that are considered forward-looking informat ...

Theratechnologies Inc. (NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ET Company Participants Denis Boucher - Vice President, Communications and Corporate Affairs Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial Officer Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Theratechnologies Conference Call. At this time, all participants are in a listen-only mode. [Operator Instruction ...

| --- | --- | --- | --- | |-------------------------|-------|-------|--------------------------------------| | | | | | | | | | | | | | | | | NASDAQ: THTX TSX: TH | | | CORPORATE PRESENTATION March 5, 2021 | Forward-Looking Information | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | The following presentation contains statements that are considered forward-looking informatio ...

Theratechnologies Inc. (NASDAQ:THTX) Q1 2020 Earnings Conference Call February 25, 2021 8:30 AM ET Company Participants Denis Boucher - VP of Communications & Corporate Affairs Paul Levesque - President, CEO & Director Philippe Dubuc - Senior VP & CFO Christian Marsolais - Senior VP & Chief Medical Officer Conference Call Participants Andre Uddin - Mackie Research Capital Edward Nash - Canaccord Genuity Corp Endri Leno - National Bank Financial, Inc Operator Ladies and gentlemen, thank you for standing by. ...

Financial Data and Key Metrics Changes - The company reported a 10% increase in consolidated revenues for Q2 2020, reaching $17.2 million, up from $15.6 million in the same quarter last year [10][34] - Trogarzo sales increased by 13.2% to $7.9 million compared to $7 million in Q2 2019, while EGRIFTA sales rose by 7.3% to $9.3 million [10][35] - The company recorded a net loss of $5.8 million or $0.08 per share, compared to a net loss of $3.2 million or $0.04 per share for the same period last year [40] Business Line Data and Key Metrics Changes - Trogarzo's net sales were up more than 13%, indicating strong performance despite operational challenges [10] - EGRIFTA sales showed a 7% increase, with the transition to EGRIFTA SV now mostly complete, allowing the company to focus on marketing EGRIFTA SV exclusively [34] Market Data and Key Metrics Changes - The company noted that the COVID-19 pandemic has created challenges in the U.S. market, particularly with shifting dynamics in states like Texas, Florida, and California [62] - The company is adapting its marketing strategies to include more webinars and educational programs to reach healthcare providers and patients [62][64] Company Strategy and Development Direction - The company aims to capitalize on the COVID-19 situation to instill a sense of urgency among physicians regarding the treatment of HIV patients who are not well-controlled [42] - There is a focus on educating healthcare providers about the serious nature of lipodystrophy, positioning it as a significant medical condition rather than a cosmetic issue [43][22] - The company plans to file a supplemental biologics license application for a new formulation of tesamorelin (F8) in early 2022, which offers greater convenience for patients [23] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the revenue growth achieved during challenging conditions, emphasizing the importance of continuing to build urgency in HIV treatment [42] - The company is optimistic about the potential for stronger growth in the latter half of 2020 as sales representatives resume traditional marketing activities [35] Other Important Information - R&D expenses increased to $3.6 million in Q2 2020, attributed to pipeline development and medical education activities [37] - The company has a strong financial position with $31.6 million in cash and bonds at the end of Q2 2020 [40] Q&A Session Summary Question: Regulatory path for NASH program and concerns about safety and efficacy - Management is monitoring the regulatory landscape and believes recent events have not significantly changed their path forward for the NASH program [48][49] Question: Updates on R&D spending and Trogarzo launch in EU - R&D spending is expected to increase as clinical programs are initiated, but specific details are not yet disclosed [53][54] - The reimbursement strategy for Trogarzo in Europe looks promising, with potential launches in Germany and Norway by the end of the year [56] Question: Sales impact in the U.S. due to COVID-19 - The company is adapting to the challenges posed by COVID-19 by increasing educational outreach through webinars and adjusting marketing strategies [62][64]

Theratechnologies Inc. (NASDAQ:THTX) Q1 2020 Earnings Conference Call April 14, 2020 8:30 AM ET Company Participants Denis Boucher - Vice President, Communications & Corporate Affairs Paul Lévesque - President & Chief Executive Officer Philippe Dubuc - Senior Vice President & Chief Financial Officer Jovan Antunovic - Chief Commercial Officer Christian Marsolais - Senior Vice President & Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets André Uddin - Mackie Research Capi ...

Theratechnologies Inc. (NASDAQ:THTX) Q4 2019 Earnings Conference Call February 25, 2020 8:30 AM ET Company Participants Denis Boucher - VP, C&CA Luc Tanguay - CEO, President Philippe Dubuc - CFO, SVP Jovan Antunovic - CCO Conference Call Participants Edward Nash - Canaccord Genuity Andre Uddin - Mackie Research Capital Corp Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Theratechnologies Conference Call. At this time, all participants are in a listen-only mode. Fo ...

Theratechnologies Inc. (THERF) Q3 2019 Results Earnings Conference Call October 8, 2019 8:30 AM ET Company Participants Denis Boucher - Vice President, Communications and Corporate Affairs Luc Tanguay - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial Officer Jovan Antunovic - Senior Vice President and Chief Commercial Officer Christian Marsolais - Senior Vice President and Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets ...

Theratechnologies Inc. (THERF) Q2 2019 Results Earnings Conference Call July 11, 2019 8:30 AM ET Company Participants Denis Boucher - Vice President, Communications and Corporate Affairs Luc Tanguay - President and Chief Executive Officer Philippe Dubuc - Senior Vice President and Chief Financial Officer Christian Marsolais - Senior Vice President and Chief Medical Officer Jovan Antunovic - Senior Vice President and Chief Commercial Officer Conference Call Participants Bryan Abrahams - RBC Capital Markets A ...

Theratechnologies Inc. (THERF) Q1 2019 Results Earnings Conference Call April 4, 2019 8:30 AM ET Company Participants Denis Boucher - IR Luc Tanguay - President and CEO Philippe Dubuc - SVP and CFO Christian Marsolais - CMO Conference Call Participants Dewey Steadman - Canaccord Brian Abrahams - RBC Capital Market Stephen Kwai - National Bank Financial Doug Loe - Echelon Wealth Partners Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies Earnings Conferen ...